Effect of Theravex Tissue Care on Implant Stability
ConditionImmediate Dental Implant Placement
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorAin Shams University
About this trial
The aim of this randomized clinical trial is to evaluate the clinical and radiographic outcomes of using Bone Bioactive Liquid (Theravex) compared to Xenograft and a combination therapy (Theravex + Xenograft) during immediate implant placement in the esthetic zone.
When a tooth is extracted and replaced immediately with a dental implant, bone grafting is often necessary to fill the gap (jumping distance) between the implant and the surrounding bone socket to support tissue healing and maintain facial contour.
Participants requiring immediate implant placement will be randomly assigned into three groups:
Group 1: Immediate implant placement using Bone Bioactive Liquid (Theravex).
Group 2: Immediate implant placement using Xenograft alone.
Group 3: Immediate implant placement using Combination Therapy (Theravex + Xenograft).
The primary outcomes will evaluate implant stability, bone dimensional changes, and soft tissue response around the implants over the follow-up period.
Eligibility criteria
Qualifiers
Patient requires extraction of a single failing or non-restorable maxillary anterior tooth or premolar.
Presence of an intact buccal bone plate (Socket Type I) with a horizontal peri-implant jumping gap ≥ 2 mm.
The implant can be placed in an ideal 3-D position with an intraoperative primary stability target of ≥ 35 Ncm.
Patient is in good general health with no systemic contraindications to implant surgery.
Disqualifiers
Pregnant and lactating females.
Heavy smokers (smoking ≥ 10 cigarettes per day).
Patients with poor oral hygiene.
Patients with occlusal or malalignment problems.
Trial design
Treatments tested in this trial
- Bone Bioactive Liquid
- Bovine-derived Xenograft
- Immediate Implant Placement
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov